Exploring In Vitro Potential of Royal Jelly Against Glioblastoma and Neuroblastoma: Impact on Cell Proliferation, Apoptosis, Cell Cycle, and Biomolecular Content

Nihal Simsek Ozek

DOI: https://doi.org/10.1039/d3an01840g

2024-01-31

The Analyst

Abstract:Neuroblastoma and glioblastoma are the most commonly seen nervous system tumors, and their treatment is challenging. Relatively safe and easy acquisition of the nutraceutical natural products make them suitable candidates for anticancer research. Royal jelly (RJ), a superfood, has many biological and pharmacological activities. This study was conducted to, for the first time, elucidate its anticancer efficiency, even in high doses, on neuroblastoma and glioblastoma through cell viability, apoptosis, and cell cycle and biomolecular content evaluation. We performed a range of 1.25-10 mg/mL of RJ for 48h. Cell viability assays revealed a notable cytotoxic effect of RJ in concentration-dependent. A high dose of RJ treatment significantly increased the apoptotic cell population of both cells. Furthermore, we observed G0-G1 phase arrest in neuroblastoma cells but G2-M arrest in glioblastoma cells. All these cellular changes are closely associated with the alterations of the macromolecular makeup of the cells, such as decrased saturated lipid, protein, DNA and RNA amount, protein conformational change, decreased protein phosphorylation and increased protein carbonylation. These cellular changes is associated with RJ triggred-ROS formation. The clear segregation between the control and the RJ-treated groups proved these changes, obtained from the unsupervised and supervised chemometric analysis. RJ has good anticancer activity against nervous system cancers and could be safely used with current treatment strategies.

chemistry, analytical